Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: GARY P GROBBEL who wrote (99804)	9/17/2010 11:01:50 AM
From: GARY P GROBBEL	Read Replies (1) \| Respond to of 120415

HEMA.ob...$.61...mentioned them yest and they are trading bit this am at .61 up .04. There is an initial contract back in late spring --below--which plants the HEMA flag smack into the cell therapy with none other than Dendreon (Nasdaq $41.83. It is for this reason, and the rapidly improving numbers from just the first qtr to the second qtr plus some other aspects I don't have time to talk about here but anyway they seem well undervalued to me based just on their short term horizon alone...and chart technicals are pointing higher---only 10m shares out and you know what that infers. stockcharts.com HemaCare Announces First Commercial Cell Therapy Collection Agreement May 20, 2010 13:00 UTC HemaCare Corporation (OTCBB: HEMA) today announced an agreement with Dendreon Corporation (NASDAQ: DNDN) to provide cellular collection services in Los Angeles and Maine for their new autologous cellular immunotherapy, PROVENGE® (sipuleucel-T). This personalized medicine is Dendreon’s lead product and is the first autologous cellular immunotherapy specifically designed to engage patients’ own immune systems to treat cancer. HemaCare currently leverages its expertise in automated cell collection (apheresis) and processing of blood products to provide specialty collection services to Dendreon and other organizations conducting cell therapy research and clinical trials. This agreement with Dendreon is the first commercial cell therapy collection agreement for HemaCare. Commenting on the new agreement, Pete van der Wal, HemaCare’s President and CEO, stated, “We are delighted to have been selected as one of Dendreon’s collection partners for PROVENGE®. Specialty collection services are an increasingly important part of our business model because we directly leverage our personnel, equipment, facilities, licensure, manufacturing protocols, and hospital relationships to help advance cell therapy research and commercialization.” Van der Wal continued, “This is an exciting field that holds much promise for HemaCare’s long-term growth as well as for patients.” ABOUT HEMACARE CORPORATION Founded in 1978, HemaCare provides customized collection and delivery of blood products and services. The Company collects, processes, purchases and distributes blood products to hospital and research related organizations and provides blood related services, principally therapeutic apheresis procedures, stem cell collection and other blood treatments to patients with a variety of disorders.